Older Patients May Have More Frequent Seizures among Children Diagnosed as Benign Convulsions with Mild

Su Jeong You1

  • 1Department of Pediatrics, Inje University College of Medicine, Sanggye Paik Hospital, Seoul, Korea.

Neuropediatrics
|February 5, 2020
PubMed

Insights

Benign convulsions with mild gastroenteritis (CwG) seizures are often mild, but older children may experience more frequent and prolonged seizures. Age is a key factor influencing seizure severity in CwG, potentially necessitating anticonvulsant treatment in older pediatric patients.

Area of Science:

  • Pediatrics
  • Neurology

Background:

  • Benign convulsions with mild gastroenteritis (CwG) typically do not require treatment.
  • Anticonvulsant medication may be necessary for patients experiencing multiple or prolonged seizures.

Purpose of the Study:

  • To identify factors influencing the number or duration of seizures in children with CwG.
  • To investigate the relationship between patient age and seizure characteristics in CwG.

Main Methods:

  • Retrospective analysis of medical records from 105 children diagnosed with CwG.
  • Comparison of seizure frequency and duration between different age groups.

Main Results:

  • A significant positive correlation was found between patient age and seizure frequency in CwG.
  • Older children (over 20 months) experienced significantly more frequent seizures compared to younger children.
  • Patients receiving anticonvulsants were older and had more frequent and longer seizures.

Conclusions:

  • Age is a significant factor associated with seizure frequency in CwG.
  • Older children with CwG may require anticonvulsant treatment due to increased seizure frequency and duration.
Abstract

Related Concept Videos

Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.2K
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.1K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.1K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
743
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
186
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
548